Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
35 nM 75 nM 75 nM >10 μM >10 μM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NFnVdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEK4NFYh|ryP MVXTRW5ITVJ?
KS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fVd2lEPTB;MD6wN|g{PSEQvF2= M3myT3NCVkeHUh?=
TE-11 NVrvNIRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTHfWZKSzVyPUCuNFc5OjJizszN NHTFbnBUSU6JRWK=
EW-1 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTuTWM2OD1yLkC4OVg2KM7:TR?= MoXSV2FPT0WU
HMV-II M1rxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLidWhKSzVyPUCuNFg5PDZizszN NIDUOmhUSU6JRWK=
COLO-205 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnueWNmUUN3ME2wMlExPDV2IN88US=> NU\xW241W0GQR1XS
ES1 M{TN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUC2PVYh|ryP NUDQSGV2W0GQR1XS
GDM-1 NGDZdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMUO2O|Ih|ryP NV3Td2JrW0GQR1XS
ML-2 M3\xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz4TWM2OD1yLkG1PFk3KM7:TR?= MYTTRW5ITVJ?
Saos-2 M1uxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMU[1NlYh|ryP MV3TRW5ITVJ?
NCI-H1355 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu2TWM2OD1yLkG4NVM2KM7:TR?= MXnTRW5ITVJ?
G-401 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPPTWM2OD1yLkG4NlMh|ryP M1XVR3NCVkeHUh?=
EW-16 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T5bWlEPTB;MD6xPFc4PyEQvF2= MXPTRW5ITVJ?
EW-7 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfUXIN{UUN3ME2wMlE5QDhzIN88US=> NH;jfmFUSU6JRWK=
NCI-H727 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnHcWc1UUN3ME2wMlE6Pzl2IN88US=> M3rrXnNCVkeHUh?=
LCLC-97TM1 NGrnNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHWOZlrUUN3ME2wMlIxQTV3IN88US=> MVvTRW5ITVJ?
NCI-H650 NYfZRYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17EemlEPTB;MD6yNVM5PCEQvF2= M4rYR3NCVkeHUh?=
NCI-H2122 M{G3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O4PGlEPTB;MD6yN|I6QSEQvF2= MV\TRW5ITVJ?
SK-N-DZ M{LFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDJU5RKSzVyPUCuNlM3QThizszN MX\TRW5ITVJ?
HT-29 NEjae3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLCZ25IUUN3ME2wMlI1OjR6IN88US=> MUTTRW5ITVJ?
LB771-HNC NWXPbIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMkW5NVUh|ryP NEPkUW5USU6JRWK=
HT-144 NH7IVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTyVpl1UUN3ME2wMlI3OTlzIN88US=> M2j2cXNCVkeHUh?=
LAN-6 NF7iTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMk[zOFgh|ryP M2OySnNCVkeHUh?=
EW-18 NVvWZ5hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[1PZVSUUN3ME2wMlI4ODBzIN88US=> NF:2[WNUSU6JRWK=
LS-1034 M2jNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn3TWM2OD1yLkK3NVMzKM7:TR?= MojSV2FPT0WU
EW-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPhfXJSUUN3ME2wMlI5PDN{IN88US=> MUjTRW5ITVJ?
SNU-C1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HNZmlEPTB;MD6yPVMyOyEQvF2= NUDmTJhnW0GQR1XS
RS4-11 NVzSVmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUizR3U2UUN3ME2wMlM{PzV6IN88US=> Ml\SV2FPT0WU
ES4 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHhcGc{UUN3ME2wMlQyODN6IN88US=> MmD3V2FPT0WU
COLO-320-HSR NYfGfXpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNEGzOlgh|ryP MULTRW5ITVJ?
NB10 NFjmWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrzTWM2OD1yLkS1OFM4KM7:TR?= MWrTRW5ITVJ?
BFTC-905 NEnKOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;nRmlEPTB;MD60Olc2QCEQvF2= M3v5fHNCVkeHUh?=
A375 NFiwfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nwNmlEPTB;MD60O|YyPyEQvF2= MVrTRW5ITVJ?
SJRH30 NXjzV2xTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXizZlhlUUN3ME2wMlUxQDJ{IN88US=> NGLjXmVUSU6JRWK=
NOS-1 NWniV44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjpOpVKSzVyPUCuOVIzPjdizszN NInQeoRUSU6JRWK=
SIG-M5 NVGwNphST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XzTmlEPTB;MD61N|U2PyEQvF2= NYTifJN5W0GQR1XS
DOK M3XqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorVTWM2OD1yLkW1OkDPxE1? NXG3TVdvW0GQR1XS
NB69 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHJNVJRUUN3ME2wMlU5OjV5IN88US=> M1zxOHNCVkeHUh?=
SK-NEP-1 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwNkCyN|Yh|ryP MXPTRW5ITVJ?
SK-MM-2 NGDnb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLuXopKSzVyPUCuOlU1QTFizszN M{XGNHNCVkeHUh?=
NCI-H358 NWDNWmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwNkewPFIh|ryP NIfyPJVUSU6JRWK=
RH-1 M4Dsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Gb2lEPTB;MD63OFg2QSEQvF2= M1T1PXNCVkeHUh?=
NH-12 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPubZVKSzVyPUCuO|YxPDZizszN MYHTRW5ITVJ?
TE-12 NFXlXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXR[JpKSzVyPUCuO|Y1QDZizszN NYr5U5ZNW0GQR1XS
COLO-668 M3rDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjQeZFFUUN3ME2wMlg1PjZ4IN88US=> NGHjW|BUSU6JRWK=
PANC-08-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPOXmRKSzVyPUCuPFY{PzdizszN NFrZfXpUSU6JRWK=
HCC2998 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vDO2lEPTB;MD64PFI3OyEQvF2= NXzyR4tVW0GQR1XS
ABC-1 M2rDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwOUCzOVIh|ryP NFjYV5hUSU6JRWK=
ES6 NGDR[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXofGRKSzVyPUCuPVExPjZizszN MkXVV2FPT0WU
SNU-387 NUKxeIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIizZ4RKSzVyPUCuPVk{QTNizszN NUXscFV2W0GQR1XS
CMK NFXiPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPEOHllUUN3ME2wMlk6QTJ7IN88US=> MmjGV2FPT0WU
SJSA-1 NHzodY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\tNJBXUUN3ME2xMlA{PjV|IN88US=> M2fjTnNCVkeHUh?=
SIMA Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Pe3hKSzVyPUGuNFY5OjVizszN NX7pRWhQW0GQR1XS
ES3 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjwTWM2OD1zLkGyNlk4KM7:TR?= NX3Edmh1W0GQR1XS
IGROV-1 NYL3ZYVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3tTWM2OD1zLkG1OFQ1KM7:TR?= NIPhRlFUSU6JRWK=
MEL-JUSO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fId2lEPTB;MT6xOVc2QSEQvF2= Ml7tV2FPT0WU
T84 NUTEWpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH25VYJKSzVyPUGuNlA6OTRizszN MnfRV2FPT0WU
CAL-85-1 M{\0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjXfmNKSzVyPUGuNlMyOzhizszN NV:0UlhOW0GQR1XS
RD MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;nTWM2OD1zLkK2OFU2KM7:TR?= M{DEVHNCVkeHUh?=
TE-8 M3OzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvYRlRwUUN3ME2xMlMyPDZ{IN88US=> MkPQV2FPT0WU
L-363 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPFU3N3UUN3ME2xMlM1OjB6IN88US=> MULTRW5ITVJ?
EKVX NIjpVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwM{S1Olgh|ryP NGDKbJFUSU6JRWK=
SK-MEL-3 NVzMfGMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwNEi1OVYh|ryP M3T5NXNCVkeHUh?=
TGBC24TKB NG\MT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorXTWM2OD1zLkWwNVk{KM7:TR?= M1rKNHNCVkeHUh?=
NCI-H1770 NHfo[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwNUGxNVMh|ryP Ml;nV2FPT0WU
HuH-7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwNkCwPVgh|ryP NVzJfYZSW0GQR1XS
HL-60 NVflblhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne1TWM2OD1zLk[2PVI5KM7:TR?= NEPGdpNUSU6JRWK=
TE-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwN{C5OFUh|ryP NG\TUIpUSU6JRWK=
LC-2-ad MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV62flNMUUN3ME2xMlc{QDh5IN88US=> M1rTPHNCVkeHUh?=
LB647-SCLC M13rOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED2UFdKSzVyPUGuO|Y2QDNizszN Mk\BV2FPT0WU
NCI-H2171 NWGzeI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrSPJdxUUN3ME2xMlc4PzF4IN88US=> MoLYV2FPT0WU
SK-PN-DW MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwOUGyPVgh|ryP Mn\4V2FPT0WU
MC-IXC NXjRVmNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC2TWM2OD1zLkm4PVgh|ryP MknyV2FPT0WU
LS-513 NWHRNVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfYTWM2OD1{LkC1N|A2KM7:TR?= MoW1V2FPT0WU
EW-3 Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfOTWM2OD1{LkC5PFQ1KM7:TR?= NFfRTI1USU6JRWK=
OPM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofRTWM2OD1{LkGwNkDPxE1? NG\FXZVUSU6JRWK=
LP-1 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfUfndvUUN3ME2yMlI2QDB5IN88US=> NGm3VI5USU6JRWK=
LU-134-A M3vjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DlUGlEPTB;Mj6yO|ch|ryP M4DLeHNCVkeHUh?=
CP66-MEL MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiyOWJKSzVyPUKuNlkxOTRizszN NVjrcGdzW0GQR1XS
HCC1143 M37vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36xdGlEPTB;Mj60OVM3QCEQvF2= NEnodohUSU6JRWK=
LOXIMVI MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HGTmlEPTB;Mj62NFIyKM7:TR?= NFzXdHBUSU6JRWK=
TE-10 NYnONIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnudIFzUUN3ME2yMlcxQDN6IN88US=> NYHMdlhLW0GQR1XS
NCI-H1882 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rYXWlEPTB;Mj63OVIzPyEQvF2= NXnrTVhOW0GQR1XS
CHP-126 NUj6SlExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCXYsyUUN3ME2yMlc3OzF5IN88US=> M3vQdXNCVkeHUh?=
NCI-H1623 NVy4S2g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ES3l2UUN3ME2yMlkzODJ2IN88US=> Mo\DV2FPT0WU
GB-1 M4\xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3aTWM2OD1{LkmzOFA1KM7:TR?= MVvTRW5ITVJ?
RCC10RGB NXTafIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwOUWyPFEh|ryP MWXTRW5ITVJ?
NCI-H2141 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHBWnlKSzVyPUKuPVY5QTZizszN NITpS41USU6JRWK=
GI-ME-N MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KyW2lEPTB;Mz6wNFU3PSEQvF2= NVHTTVdXW0GQR1XS
NCI-H526 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XTcmlEPTB;Mz6wOFA5PSEQvF2= MV7TRW5ITVJ?
NCI-H747 NUjzUmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnrPGFrUUN3ME2zMlA1QTl{IN88US=> M33HOHNCVkeHUh?=
SNU-423 NWG2VHlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwMkCzNVMh|ryP NXjx[4hGW0GQR1XS
A427 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqyTWM2OD1|LkK1Olk6KM7:TR?= NYnHWoNrW0GQR1XS
CAL-12T NF6w[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTaTWM2OD1|LkSwO|E{KM7:TR?= M{XZRXNCVkeHUh?=
LU-99A NYHsd5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDvTWM2OD1|LkS3NVA2KM7:TR?= NWjLVnZZW0GQR1XS
MS-1 NWfaeYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\hZWZKSzVyPUOuOVM1OjlizszN NFjTflJUSU6JRWK=
SK-LU-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qzcWlEPTB;Mz63OlI6PSEQvF2= NHXBPGdUSU6JRWK=
SW837 NIPNenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\IfnNKSzVyPUOuO|Y{OzNizszN MoXHV2FPT0WU
ES8 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTNwOEO4O|ch|ryP M{TIenNCVkeHUh?=
MZ2-MEL M1;icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLQ[XRHUUN3ME2zMlkzODh4IN88US=> M{DrNXNCVkeHUh?=
TGW M3qycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3exRWlEPTB;ND6wNVMyOSEQvF2= NHW0U4JUSU6JRWK=
GP5d M4DyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M331WWlEPTB;ND6wOVM3OiEQvF2= NUTUbZhjW0GQR1XS
BB49-HNC M{S0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMUWyNVMh|ryP MV3TRW5ITVJ?
NB13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRwMk[4PFch|ryP M4qwb3NCVkeHUh?=
NTERA-S-cl-D1 NE\Zd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRwMki2NVUh|ryP M320XHNCVkeHUh?=
NCI-H1648 M1nXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP3TWM2OD12LkK5PFE6KM7:TR?= MoGyV2FPT0WU
LCLC-103H NHHjSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXsS41IUUN3ME20MlMzOTl3IN88US=> NIDBb2ZUSU6JRWK=
LS-411N NGT2RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M321dmlEPTB;ND60OFg5PSEQvF2= M17QTHNCVkeHUh?=
NCI-H1092 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3mcINKSzVyPUSuOFU3QDdizszN NWXwe3dsW0GQR1XS
PANC-10-05 NXe2TXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD12Lk[5PFQh|ryP MlHyV2FPT0WU
DK-MG M1K3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof5TWM2OD12LkiwPVM{KM7:TR?= NF7SV2VUSU6JRWK=
OVCAR-5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;sTWM2OD12LkixNlI3KM7:TR?= NGjhSWFUSU6JRWK=
CAL-39 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKzV2VKSzVyPUSuPFc3PyEQvF2= MX;TRW5ITVJ?
TE-441-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmxZ2NHUUN3ME20MlkxPTN5IN88US=> M37zTHNCVkeHUh?=
MOLT-16 NW[yNnlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRwOUWyOVMh|ryP M2HaVHNCVkeHUh?=
MCF7 M3u0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\WU|hkUUN3ME21MlE1PTF5IN88US=> MonlV2FPT0WU
CAPAN-1 NYLwWWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1NmlEPTB;NT6yOVcxPyEQvF2= MYDTRW5ITVJ?
PSN1 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYc3BDUUN3ME21MlI4OjN3IN88US=> NGXQeVFUSU6JRWK=
NCI-H292 NXq2SXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG4WI9uUUN3ME21MlMxODR2IN88US=> Ml2yV2FPT0WU
CPC-N MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTVwM{m0NVkh|ryP M2jnTXNCVkeHUh?=
DoTc2-4510 NFHNVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofDTWM2OD13LkS1N|cyKM7:TR?= MmHUV2FPT0WU
LB1047-RCC NFi5[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L6bmlEPTB;NT61OVk{OyEQvF2= NFu0cIJUSU6JRWK=
MHH-ES-1 M3;zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPyTWM2OD13LkW5PVA4KM7:TR?= MlHYV2FPT0WU
NMC-G1 M{mzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTVwN{CyNlch|ryP NIXNVVBUSU6JRWK=
SW1710 M2DMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTVwN{S3OVEh|ryP NXXWe3BFW0GQR1XS
YAPC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni5TWM2OD13Lke2NlAyKM7:TR?= MV;TRW5ITVJ?
22RV1 NVLMWmZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTDWnR6UUN3ME21MlgxODF7IN88US=> MmX1V2FPT0WU
COLO-679 NH7SbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SzNWlEPTB;NT64PFk1QCEQvF2= M3fJRnNCVkeHUh?=
TCCSUP NF7tSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfrW|dTUUN3ME21Mlk{OjV7IN88US=> M2raVHNCVkeHUh?=
C2BBe1 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rKcmlEPTB;NT65N|k4KM7:TR?= NEnpZY9USU6JRWK=
TE-15 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jYc2lEPTB;Nj6wOlYxPSEQvF2= MmXYV2FPT0WU
SCLC-21H Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH5ZpJKSzVyPU[uNVA5PDNizszN NVzVWJhKW0GQR1XS
EoL-1-cell MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\MNmlEPTB;Nj6xOlU3OyEQvF2= M{C4cnNCVkeHUh?=
NKM-1 NWXvR|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZwMU[3NUDPxE1? M{KzcnNCVkeHUh?=
NCI-H1304 M1HZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLZdYNbUUN3ME22MlI4PDJ6IN88US=> NWLzUG1TW0GQR1XS
NB6 M2POWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZwMkm2NlIh|ryP Mk\1V2FPT0WU
NALM-6 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XSOGlEPTB;Nj6zN|I{KM7:TR?= NUfPTmFrW0GQR1XS
NCI-H522 NUH5Xm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS4UmNGUUN3ME22MlM{OzB4IN88US=> Mom2V2FPT0WU
MV-4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH6cJFKSzVyPU[uN|cxPzlizszN Mn;wV2FPT0WU
LB2241-RCC NWXyRYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTZwM{i2Olch|ryP MkHYV2FPT0WU
NCI-H1417 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXtclE1UUN3ME22MlQxQDR5IN88US=> Mn;VV2FPT0WU
HT-1197 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSzcGFKSzVyPU[uOVcyOjJizszN MmLsV2FPT0WU
P30-OHK MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu2e4FXUUN3ME22MlYzPzdizszN M4fDSHNCVkeHUh?=
ALL-PO M1rt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M130S2lEPTB;Nj63NVkyPiEQvF2= MlfsV2FPT0WU
OVCAR-4 NGLZRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mke2TWM2OD14Lke1OFA2KM7:TR?= M4n3SnNCVkeHUh?=
HCC2157 NXTZV|FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XHemlEPTB;Nj63O|Q4PSEQvF2= M3zjeXNCVkeHUh?=
NCI-H838 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zXdmlEPTB;Nj65OlQ6KM7:TR?= MUXTRW5ITVJ?
NCI-H1299 NWjPR4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXFTWM2OD14Lkm3NFkh|ryP NFSyTmJUSU6JRWK=
SW954 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTdwMkCwOlgh|ryP NF\EVVJUSU6JRWK=
NCI-H441 NVPROmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTdwM{SwOlUh|ryP NVHBNnBrW0GQR1XS
SK-MEL-2 M3nufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX4W4pQUUN3ME23MlQ5Ozd|IN88US=> MorIV2FPT0WU
KARPAS-45 NV;OZld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW1[ohKSzVyPUeuOlU6OjlizszN NU\XfnZJW0GQR1XS
CAL-54 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq4OI5KSzVyPUeuPFI6PzdizszN MmT3V2FPT0WU
KYSE-180 NH3qPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTLTWM2OD15Lki4PVQyKM7:TR?= Ml;YV2FPT0WU
NCI-H187 NUjC[HN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0WGlEPTB;Nz65OVk1PyEQvF2= NUnhXGoyW0GQR1XS
RT-112 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRThwMEm2O|ch|ryP MYPTRW5ITVJ?
NCI-H1437 NXXYbotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTEcos2UUN3ME24MlA6Pzl3IN88US=> NV\pW24{W0GQR1XS
SNU-449 NGLyPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUezO4pjUUN3ME24MlI5Ojd{IN88US=> MlfvV2FPT0WU
HCC1187 NVzFOZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS0TWhKSzVyPUiuNlk{QTFizszN MX\TRW5ITVJ?
NCI-H2030 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwM{e3NVQh|ryP NUPoUWlJW0GQR1XS
HuO-3N1 NGLNT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DlVGlEPTB;OD6zO|g1PCEQvF2= M4WzZnNCVkeHUh?=
COLO-792 M3rPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnsTWM2OD16LkSxOVI4KM7:TR?= MkLJV2FPT0WU
MIA-PaCa-2 M3nhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTpZlFKSzVyPUiuPFU2ODhizszN NV;4RllHW0GQR1XS
SK-N-FI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjucGlKSzVyPUmuNFQzPSEQvF2= NVr2[WdjW0GQR1XS
MMAC-SF MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfUV5c5UUN3ME25MlA6PzVzIN88US=> NHPwOI5USU6JRWK=
NCI-H28 NI\5[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:zbFBnUUN3ME25MlExPDZ7IN88US=> MYDTRW5ITVJ?
ETK-1 NXLlWIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTlwMkm5O|Qh|ryP NVnSO5JzW0GQR1XS
NCI-H1993 NHP4TZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fiUmlEPTB;OT60OFI3OSEQvF2= MoP4V2FPT0WU
no-11 MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7NXYZKSzVyPUmuOFcyOiEQvF2= MkP3V2FPT0WU
ChaGo-K-1 M{\D[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonFTWM2OD17LkWxOVg{KM7:TR?= NHjEeZhUSU6JRWK=
NCCIT MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPTeHlKSzVyPUmuOVMyPjlizszN M37vXHNCVkeHUh?=
SAS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrITWM2OD1zMD6yOFgh|ryP M4DoXXNCVkeHUh?=
A673 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFyLkO3NFQh|ryP NWrkWGl[W0GQR1XS
NCI-H1522 NXfuc2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHyTWM2OD1zMD6zO|A4KM7:TR?= MnvyV2FPT0WU
NCI-H810 NEjLNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPiSpliUUN3ME2xNE4{QTB5IN88US=> NWLLT2pCW0GQR1XS
IST-MES1 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLjTWM2OD1zMD60OVY1KM7:TR?= NVHSZWJGW0GQR1XS
GR-ST MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\CTWM2OD1zMD61NFI1KM7:TR?= NGLQfo9USU6JRWK=
SUP-T1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LONmlEPTB;MUCuO|MyPyEQvF2= Moe5V2FPT0WU
NB5 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi4XoYzUUN3ME2xNE46ODJ{IN88US=> MnTuV2FPT0WU
MZ1-PC M{H3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\xdnFKSzVyPUGwMlk2PzFizszN NGHvSIxUSU6JRWK=
SK-CO-1 M2PkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFyLkm5N|Eh|ryP NHT2cnRUSU6JRWK=
Capan-2 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;NTWM2OD1zMT6zNVk5KM7:TR?= NUTBdXVpW0GQR1XS
697 NXTFeIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFzLk[3OVch|ryP NIjXOZdUSU6JRWK=
REH M13BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFzLke0OVEh|ryP MkHhV2FPT0WU
GI-1 M3rQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LlXWlEPTB;MUGuPFYyPSEQvF2= Mn\SV2FPT0WU
BB65-RCC M4LsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHETWM2OD1zMj6wPVE3KM7:TR?= NX;KOFJuW0GQR1XS
NCI-H1651 NHf2dHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF{LkK0O|gh|ryP NYr6TWg2W0GQR1XS
NCI-H1618 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH22NmtKSzVyPUGyMlM6PzZizszN NEToWZNUSU6JRWK=
NCI-H2081 M4LHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf2fWRKSzVyPUGyMlYyPDFizszN NYfSdYcxW0GQR1XS
GCIY NGi1SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG3UG5EUUN3ME2xNk44OjF|IN88US=> NUTZTYRyW0GQR1XS
NY NIDRT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF|LkC2OFMh|ryP M3jwUXNCVkeHUh?=
PANC-03-27 M1u1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XBR2lEPTB;MUOuNFgxPyEQvF2= MYfTRW5ITVJ?
BHY MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\GTWM2OD1zMz6yNVIyKM7:TR?= NE\KZYlUSU6JRWK=
SK-OV-3 NULtSGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq2TWM2OD1zMz6zO|Y{KM7:TR?= M2TqXnNCVkeHUh?=
5637 NXi1W3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XMcWlEPTB;MUOuO|c2QSEQvF2= M{\PNnNCVkeHUh?=
LC-1F M2K3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3t[pdCUUN3ME2xOE4xOzV4IN88US=> MlPLV2FPT0WU
SNB75 NETJN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF2LkCzPFMh|ryP NXztZ4xQW0GQR1XS
CHP-212 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF2LkC0OlQh|ryP NFzQWpJUSU6JRWK=
HT-1376 M{PKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\pRoY3UUN3ME2xOE4yOTJ4IN88US=> NXXVbG5WW0GQR1XS
MONO-MAC-6 NGPGcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDVnN[UUN3ME2xOE4yPTB{IN88US=> NFLBeoFUSU6JRWK=
CA46 NVzaW4pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rvVGlEPTB;MUSuNVgzPyEQvF2= M4jROnNCVkeHUh?=
SCC-15 NXXBd41IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzFNVdKSzVyPUG0MlU2QDNizszN NYrOb4U5W0GQR1XS
ATN-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF2Lk[2Nlch|ryP MXfTRW5ITVJ?
NCI-H2405 NHvr[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonZTWM2OD1zND64NVU4KM7:TR?= NX\FVnVtW0GQR1XS
NCI-H716 M165TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7yZ2xKSzVyPUG0Mlg1QTNizszN MnjKV2FPT0WU
SW620 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj1SG1UUUN3ME2xOE46ODF2IN88US=> NWfYXI1lW0GQR1XS
NCI-H226 M1XLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnVTWM2OD1zND65NFg2KM7:TR?= NHPFN|FUSU6JRWK=
SW962 M3m5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBO2lEPTB;MUSuPVQ{OiEQvF2= MVvTRW5ITVJ?
KYSE-150 NVjzT5ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojnTWM2OD1zND65OVUh|ryP M4P2XnNCVkeHUh?=
OCUB-M NXrk[XhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TCe2lEPTB;MUSuPVg5OyEQvF2= MWjTRW5ITVJ?
ES7 MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfmXZhKSzVyPUG1MlA6QDRizszN NHvob2FUSU6JRWK=
SW1463 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF3LkSyNlMh|ryP MULTRW5ITVJ?
CAKI-1 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH2TWM2OD1zNT61N|Q3KM7:TR?= MXHTRW5ITVJ?
MKN28 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPqTWM2OD1zNT61OFc6KM7:TR?= MVfTRW5ITVJ?
SW13 M3PXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF3Lk[xPEDPxE1? NUTx[nVDW0GQR1XS
A3-KAW MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF3Lkm2PVch|ryP NIPZfoVUSU6JRWK=
LU-65 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PJbWlEPTB;MUWuPVc3QCEQvF2= M3O3bHNCVkeHUh?=
Calu-1 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrBRZpKSzVyPUG2MlA{PjhizszN M2LzN3NCVkeHUh?=
ST486 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4LkC0N|Eh|ryP M4D2RnNCVkeHUh?=
BB30-HNC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF4LkGyOFYh|ryP NFu2SlFUSU6JRWK=
EGI-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ydHRKSzVyPUG2MlQ1PiEQvF2= NVLhOIRXW0GQR1XS
SH-4 M{PITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF4LkS3N|Eh|ryP MnXyV2FPT0WU
MN-60 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF5LkKyPVch|ryP MmLIV2FPT0WU
MPP-89 NImxS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r4eWlEPTB;MUeuNlQ2QSEQvF2= NEmyUoJUSU6JRWK=
A2780 NIrQSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3CTWM2OD1zNz60NVM6KM7:TR?= M2nFb3NCVkeHUh?=
Daoy M1T6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF5LkS2PVUh|ryP NY\l[IxmW0GQR1XS
NCI-H2126 M2\u[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzqTWM2OD1zNz60O|cyKM7:TR?= MUTTRW5ITVJ?
NCI-H1563 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjPdY9KSzVyPUG3MlQ6OTdizszN NYLzWYNSW0GQR1XS
8-MG-BA MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTIW4hpUUN3ME2xO{43PjR6IN88US=> MY\TRW5ITVJ?
786-0 NEDLdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lse2lEPTB;MUeuPFM2OyEQvF2= NGfWd29USU6JRWK=
AM-38 M3fRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7VNYhKSzVyPUG3Mlk{ODZizszN NUPtfG05W0GQR1XS
COLO-824 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF6LkS0N|Yh|ryP NETzfoJUSU6JRWK=
SK-MEL-30 NHXyVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvxTWM2OD1zOD61NFgzKM7:TR?= NULrdI9OW0GQR1XS
CESS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXMTGhKSzVyPUG4Mlc3ODlizszN M1XTNHNCVkeHUh?=
BL-70 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF6LkixOVYh|ryP MlGzV2FPT0WU
NCI-H2170 M1r1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD1zOD65NVc6KM7:TR?= NUTzdJlwW0GQR1XS
HT-3 NV7nTGxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fsWmlEPTB;MUiuPVg{KM7:TR?= M1\PS3NCVkeHUh?=
BOKU NWTJZ4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vwXWlEPTB;MUmuNFM5OSEQvF2= M3nCO3NCVkeHUh?=
HPAF-II MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L0S2lEPTB;MUmuN|AyPSEQvF2= NGX1[ZpUSU6JRWK=
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF7LkS3OlUh|ryP MmPqV2FPT0WU
MC-CAR NXHselV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf4TWM2OD1zOT62N|E{KM7:TR?= MVrTRW5ITVJ?
BHT-101 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF7Lke3O{DPxE1? MVjTRW5ITVJ?
SW1783 M1XBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfOcHBKSzVyPUG5Mlc5ODZizszN MnHTV2FPT0WU
KP-N-YN MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DSTGlEPTB;MkCuNFI3OiEQvF2= MlLMV2FPT0WU
LU-165 NGm0WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfhTWM2OD1{MD61OVcyKM7:TR?= M2DpSnNCVkeHUh?=
GOTO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG1bJBKSzVyPUKwMlY1PTFizszN NWG4[5BGW0GQR1XS
EFM-19 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLxTWM2OD1{MT6wO|E3KM7:TR?= M13xSnNCVkeHUh?=
CTV-1 M1LETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W1cWlEPTB;MkGuNVA2PCEQvF2= M{\zNnNCVkeHUh?=
HEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJzLkSyNVYh|ryP MlfhV2FPT0WU
SNU-C2B MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUflXFZmUUN3ME2yNU41OjZizszN M331eXNCVkeHUh?=
ECC4 NUXFT4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJzLkewO{DPxE1? MmDrV2FPT0WU
NEC8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoraTWM2OD1{MT64N|Y5KM7:TR?= MVTTRW5ITVJ?
KMOE-2 M1zQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjzRVNKSzVyPUKxMlg6OjFizszN MlzFV2FPT0WU
NCI-H524 NF\nTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrQNFg6UUN3ME2yNk4xQDB6IN88US=> M3rGRXNCVkeHUh?=
WSU-NHL M{PSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vmfGlEPTB;MkKuNVU4PyEQvF2= MWLTRW5ITVJ?
SF126 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DoNmlEPTB;MkKuNlQ3QSEQvF2= NYjucFNqW0GQR1XS
HOP-92 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m4cWlEPTB;MkKuN|E3PyEQvF2= NWDoN2RSW0GQR1XS
CTB-1 M3\ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjvN2p6UUN3ME2yNk41Pjd5IN88US=> MYDTRW5ITVJ?
KYSE-270 NVm3UHU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml73TWM2OD1{Mj65N|U4KM7:TR?= NEe4ZmhUSU6JRWK=
SK-MEL-24 M4TOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTiTWM2OD1{Mz6xPFch|ryP NYHUPIhoW0GQR1XS
Calu-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ|LkKxNlgh|ryP M{fDXXNCVkeHUh?=
GAMG MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTuTWM2OD1{Mz6yN|Y4KM7:TR?= NXHPVnpQW0GQR1XS
SW1573 NWnRSWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H1R2lEPTB;MkOuO|QyPSEQvF2= M3PFUHNCVkeHUh?=
MHH-NB-11 NH75VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nFbGlEPTB;MkSuNFE6PCEQvF2= NI\KTohUSU6JRWK=
TK10 M1T6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ2LkWwNVMh|ryP Mk\sV2FPT0WU
LB373-MEL-D MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4CyfGlEPTB;MkSuOlA3PCEQvF2= NX\Jc41DW0GQR1XS
KALS-1 NH7OfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrsdHNKSzVyPUK0Mlc{OjdizszN M2XufXNCVkeHUh?=
HUTU-80 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ3LkiwN|Ih|ryP MVXTRW5ITVJ?
HuP-T3 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;QfGNKSzVyPUK2MlE3PzRizszN MoLKV2FPT0WU
OE19 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHaTWM2OD1{Nj6yNVU{KM7:TR?= MUPTRW5ITVJ?
J82 NWj0[o9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HpXWlEPTB;Mk[uNlQ4OSEQvF2= NHjicFhUSU6JRWK=
DU-4475 M1;6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fHXmlEPTB;Mk[uN|gyQSEQvF2= MkTPV2FPT0WU
DMS-53 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnoUlFKSzVyPUK2MlUyOzhizszN MmPvV2FPT0WU
COLO-741 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnWZplsUUN3ME2yOk45OzR2IN88US=> M2LZOHNCVkeHUh?=
SW48 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHuPFVKSzVyPUK2Mlg5OiEQvF2= MlXLV2FPT0WU
IGR-1 NFrpT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn2PGN4UUN3ME2yOk46OzN2IN88US=> MV;TRW5ITVJ?
639-V NEjUO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuzVJNiUUN3ME2yO{4xOjR3IN88US=> NW[1bo9mW0GQR1XS
LK-2 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LHN2lEPTB;MkeuOFE1OSEQvF2= MmrDV2FPT0WU
NCI-H2347 MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHTeVRKSzVyPUK3Mlk3QTlizszN MkDqV2FPT0WU
NCI-H2228 NU\K[YdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:3PVNbUUN3ME2yPE4xQTB3IN88US=> M130OHNCVkeHUh?=
LS-123 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ6LkGyOlIh|ryP MoHEV2FPT0WU
U031 NVHpV5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnUeoNOUUN3ME2yPE4zPTJizszN NE\zeVZUSU6JRWK=
NCI-H1792 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTkcIY5UUN3ME2yPE41PzJzIN88US=> M33LcHNCVkeHUh?=
NCI-H2087 NFuzVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD1{OD63OVUzKM7:TR?= M3rHfHNCVkeHUh?=
NCI-H2342 M2X0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ7LkWyNFgh|ryP MlzuV2FPT0WU
SW626 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vENmlEPTB;MkmuO|U3KM7:TR?= NX;NbW1{W0GQR1XS
LB2518-MEL M1zRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\s[mlEPTB;MkmuPFE2KM7:TR?= MlPSV2FPT0WU
RXF393 M3r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNyLkC5OVIh|ryP NGTjbZpUSU6JRWK=
LC4-1 M1;XUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzZTWM2OD1|MD6zNFkzKM7:TR?= MnW4V2FPT0WU
NCI-H1694 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrhRpNNUUN3ME2zNE43PjJ2IN88US=> MWrTRW5ITVJ?
K5 NIe1do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z1fWlEPTB;M{CuPVcxOiEQvF2= NX3OWVNrW0GQR1XS
HDLM-2 M3j6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPsdplKSzVyPUOwMlk4OjVizszN Mk\EV2FPT0WU
BCPAP MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HUO2lEPTB;M{GuPFM4QSEQvF2= NVzkO|lzW0GQR1XS
BC-3 NGHGXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\6TWM2OD1|Mj6xOFA{KM7:TR?= NW\6dIV2W0GQR1XS
LB996-RCC NFz5UVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rLTmlEPTB;M{KuNlM2QCEQvF2= MoDhV2FPT0WU
NCI-H2009 M2jJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jpfGlEPTB;M{KuOFk5OSEQvF2= M1zNb3NCVkeHUh?=
HTC-C3 NYK0cWRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPOGlEPTB;M{OuO|UyQSEQvF2= NGDLWGdUSU6JRWK=
LAMA-84 NHvMc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrycJA2UUN3ME2zOE41PDB5IN88US=> NYH4d45UW0GQR1XS
CCRF-CEM NH\WOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\WTWM2OD1|ND61O|E2KM7:TR?= M17yVXNCVkeHUh?=
AN3-CA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN3LkC1Olgh|ryP NHfaSnBUSU6JRWK=
NCI-H1734 NXTXbG9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK0T2lKSzVyPUO1MlI2PjFizszN NH7SVY5USU6JRWK=
Ca-Ski NF3GeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomzTWM2OD1|NT60NVAyKM7:TR?= MonRV2FPT0WU
U-266 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN3Lk[xNVQh|ryP MmLkV2FPT0WU
SBC-5 NEL4NVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfieYNwUUN3ME2zOU44PzhzIN88US=> MlPDV2FPT0WU
GT3TKB NGHheINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjaTWM2OD1|Nz6xNVUh|ryP MXjTRW5ITVJ?
MDA-MB-175-VII NXvaepBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[0TWM2OD1|Nz6yNlQ5KM7:TR?= MmjZV2FPT0WU
PFSK-1 NUPid21kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvqTWM2OD1|Nz6yOFM2KM7:TR?= NVq3N4FKW0GQR1XS
IMR-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN5LkK0PFch|ryP MUnTRW5ITVJ?
Daudi MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN5LkO1PVch|ryP M4DKPXNCVkeHUh?=
A498 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrXTWM2OD1|Nz63NlE5KM7:TR?= M2\TT3NCVkeHUh?=
SCC-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KzV2lEPTB;M{euO|g1OyEQvF2= M4f1XHNCVkeHUh?=
COLO-680N Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTlT4ZrUUN3ME2zPE4zQDh3IN88US=> MYTTRW5ITVJ?
SK-MES-1 NXLnUpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f2dGlEPTB;M{iuN|IyPSEQvF2= NF;weIVUSU6JRWK=
SR MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN6LkW0PVUh|ryP MUHTRW5ITVJ?
LNCaP-Clone-FGC M16yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Hd2lEPTB;M{iuOVY{PyEQvF2= MYPTRW5ITVJ?
SK-HEP-1 M4jCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHizWFlKSzVyPUO4Mlc5OjJizszN M3vxUHNCVkeHUh?=
BPH-1 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHR[pZKSzVyPUO4Mlg{OjlizszN NWrNVJV2W0GQR1XS
NCI-H1755 NILOOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QdWlEPTB;M{muOVgyPyEQvF2= M1nyU3NCVkeHUh?=
LXF-289 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnWe5NKSzVyPUO5MlgxQDRizszN M33We3NCVkeHUh?=
SW1088 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\hTWM2OD12MD6yNVA4KM7:TR?= M{OyZ3NCVkeHUh?=
MOLT-4 NFjBb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\3dnZiUUN3ME20NE4zQTBzIN88US=> MWDTRW5ITVJ?
AsPC-1 M3LtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\YVnpKSzVyPUSwMlQ2QDNizszN MXjTRW5ITVJ?
HOP-62 M32yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHrbWpKSzVyPUSwMlY2PjhizszN M1rpbnNCVkeHUh?=
A172 M2O1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC1TWM2OD12MD64OVEyKM7:TR?= NFLtbHhUSU6JRWK=
SN12C NI\CUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP4TWM2OD12MD65N|g2KM7:TR?= M33TTHNCVkeHUh?=
MDA-MB-231 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m3PGlEPTB;NECuPVg6QCEQvF2= MVTTRW5ITVJ?
RPMI-2650 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLMUVJKSzVyPUSxMlE2QTNizszN M3Hzb3NCVkeHUh?=
KYSE-140 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRzLkixNlMh|ryP MnnsV2FPT0WU
KINGS-1 M4Gxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR{LkS2PVch|ryP MkHvV2FPT0WU
HSC-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon1TWM2OD12Mj62OlYyKM7:TR?= M1LvfHNCVkeHUh?=
PC-14 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR|LkG4PFIh|ryP Mk\6V2FPT0WU
COR-L105 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm2TWM2OD12Mz62OVAzKM7:TR?= NFnaSoZUSU6JRWK=
BE-13 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDYNYdkUUN3ME20OE4zOzdzIN88US=> NWTMTY13W0GQR1XS
NCI-H661 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nJSGlEPTB;NESuNlk2QCEQvF2= MoL6V2FPT0WU
IST-MEL1 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjhUIxKSzVyPUS0MlM2QTlizszN M2PobHNCVkeHUh?=
HCC1806 M4TsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rmeWlEPTB;NESuOVg4OyEQvF2= M4TsPHNCVkeHUh?=
COLO-800 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR2Lki0OVMh|ryP MXLTRW5ITVJ?
IST-SL2 M1K0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vkSmlEPTB;NEWuNVI1PyEQvF2= NHnxPGxUSU6JRWK=
8305C MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR3LkOwPUDPxE1? NV7pR3ZPW0GQR1XS
UACC-62 NUfQd5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLRTWM2OD12Nj6yPFc2KM7:TR?= MWnTRW5ITVJ?
COR-L23 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR5LkG5PUDPxE1? MVXTRW5ITVJ?
EFE-184 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LlfmlEPTB;NEeuN|g5KM7:TR?= M3zCT3NCVkeHUh?=
DMS-114 M3XUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLx[4Z4UUN3ME20O{41OTR7IN88US=> M4X0R3NCVkeHUh?=
KYSE-520 NXL3SHNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i2OGlEPTB;NEiuOVMyPSEQvF2= MkXWV2FPT0WU
SNG-M MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG3RWpmUUN3ME20PU41OzRizszN MlLLV2FPT0WU
A2058 NXuzO29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlTWM2OD12OT60PFg2KM7:TR?= MV\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID